London School of Hygiene & Tropical Medicine

Agios Appoints Tsveta Milanova as Chief Commercial Officer

Retrieved on: 
Tuesday, December 6, 2022

CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023.
  • Ms. Milanova will succeed Richa Poddar, who has been with Agios since 2016 and will continue to serve as the company’s chief commercial officer until the end of the year.
  • She has been instrumental in helping make Agios what it is today.”
    Ms. Milanova joins Agios with two decades of experience in commercial leadership and global market access in the biopharmaceutical industry.
  • She spent five years at Alexion in high-impact commercial and market access roles, including senior vice president, head of U.S. commercial; senior vice president, global commercial strategy; and senior vice president, global value, access and policy.

London School of Hygiene & Tropical Medicine Selects Zenoss to Ensure Availability of IT Services

Retrieved on: 
Thursday, November 10, 2022

Zenoss Inc., the leader in AI-driven full-stack monitoring , today announced renowned research institution London School of Hygiene & Tropical Medicine (LSHTM) has selected Zenoss to provide a unified view of their IT services and operations, which are mission critical to their academics, research and students worldwide.

Key Points: 
  • Zenoss Inc., the leader in AI-driven full-stack monitoring , today announced renowned research institution London School of Hygiene & Tropical Medicine (LSHTM) has selected Zenoss to provide a unified view of their IT services and operations, which are mission critical to their academics, research and students worldwide.
  • Zenoss Cloud enables LSHTMs global IT operations and services team to have visibility and awareness across their growing and increasingly complex hybrid IT infrastructure.
  • "Zenoss is focused on enabling our customers to optimize services and operations and ensuring the performance of their IT environments," said Greg Stock, CEO of Zenoss.
  • Zenoss works with the world's largest organizations to ensure their IT services and applications are always on.

Maternova Appoints Luna Mehrain, MD, MSc, as Chief Medical Officer

Retrieved on: 
Wednesday, October 12, 2022

Maternova, Inc. , accelerating advances in maternal and infant health through innovative, accessible solutions, today announced the appointment of Luna M. Mehrain, MD, MSc, as Chief Medical Officer.

Key Points: 
  • Maternova, Inc. , accelerating advances in maternal and infant health through innovative, accessible solutions, today announced the appointment of Luna M. Mehrain, MD, MSc, as Chief Medical Officer.
  • She is a passionate clinician with a proven track record of championing health care for women and babies in resource-limited settings.
  • Her experience with prominent international organizations and expert medical knowledge make her an ideal addition to Maternova as we grow our life-saving product and technology offerings for health practitioners around the world, said Prakash Veenam, Chief Executive Officer, Maternova.
  • Maternova is a unique and trusted resource for medical innovations in newborn, obstetrics and reproductive health based on a deep understanding of the issues faced by clinicians and patients in low- and middle-income countries and humanitarian settings, said Luna Mehrain, MD, MSc, Chief Medical Officer, Maternova.

PharmaVentures' new Vice President recruited to lead Pricing and Market Access practice

Retrieved on: 
Tuesday, September 27, 2022

LONDON, Sept. 27, 2022 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.

Key Points: 
  • LONDON, Sept. 27, 2022 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.
  • Ralph has built extensive experience in Pricing and Market Access, and also in Commercial assessment, through his various roles in the pharmaceutical industry.
  • For Mundipharma, he was responsible for the access and commercial launch strategy for key brands and for developing the commercial assessments for potential assets.
  • At Pfizer, he developed market access and pricing strategies globally and across multiple disease areas for early-stage and in-market assets.

PharmaVentures' new Vice President recruited to lead Pricing and Market Access practice

Retrieved on: 
Tuesday, September 27, 2022

LONDON, Sept. 27, 2022 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.

Key Points: 
  • LONDON, Sept. 27, 2022 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.
  • Ralph has built extensive experience in Pricing and Market Access, and also in Commercial assessment, through his various roles in the pharmaceutical industry.
  • For Mundipharma, he was responsible for the access and commercial launch strategy for key brands and for developing the commercial assessments for potential assets.
  • At Pfizer, he developed market access and pricing strategies globally and across multiple disease areas for early-stage and in-market assets.

Global Impact launches new $5M research fund - Vaccine Confidence Fund II to further understand how Social Media may be leveraged to Increase Vaccination Confidence and Uptake

Retrieved on: 
Friday, August 5, 2022

This round of funding for global research will focus on harnessing the power of social media to increase vaccination confidence and uptake with an emphasis on enhancing routine immunization and educating health care workers on addressing vaccine hesitancy.

Key Points: 
  • This round of funding for global research will focus on harnessing the power of social media to increase vaccination confidence and uptake with an emphasis on enhancing routine immunization and educating health care workers on addressing vaccine hesitancy.
  • Global Impact is publishing the Full Insights Report on the first Vaccine Confidence Fund which features findings from the grantees research and insights on potential ways to drive vaccination confidence and uptake.
  • Through these partnerships, Global Impact has raised nearly $2 billion for causes such as disaster relief and global development.
  • Global Impacts reach and services are complemented by the work of its subsidiary company, Geneva Global .

OnAsset supply chain tracking device deployed to address medicine diversion in Malawi

Retrieved on: 
Thursday, August 4, 2022

DALLAS, Aug. 4, 2022 /PRNewswire-PRWeb/ -- OnAsset Intelligence recently supplied technology to a public-private research partnership to audit and combat drug shipment diversion in Malawi. Alongside the Malawi Ministry of Health, OnAsset worked with the London School of Economics and Political Science, University of North Carolina Chapel Hill and University of California San Diego to audit medicine distribution in real time using OnAsset's suite of technologies. OnAsset's solution helped the government better understand how to improve upon the delivery of health services.

Key Points: 
  • A public-private research partnership recently deployed supply chain tracking technologies to monitor shipments of medical supplies in Malawi.
  • Getting a handle on the supply chain is an important step to improving health outcomes.
  • DALLAS, Aug. 4, 2022 /PRNewswire-PRWeb/ -- OnAsset Intelligence recently supplied technology to a public-private research partnership to audit and combat drug shipment diversion in Malawi.
  • "By placing OnAsset tracking devices and a monitoring warning label on medicine being shipped from Malawi Central Medical Stores Trust to healthcare facilities in Southern Malawi, researchers were able to gain visibility into the breakdown in medicine delivery."

OS-Climate Unleashes Power of Open Source to Develop Data and Tools Required to Meet the Paris Climate Goals

Retrieved on: 
Wednesday, July 27, 2022

OS-Climate released for public collaboration three analytic tools critical to tackling the climate crisis.

Key Points: 
  • OS-Climate released for public collaboration three analytic tools critical to tackling the climate crisis.
  • Through our collaboration with OS-Climate we can develop open source tools based on proper data far more rapidly than we could on our own.
  • Linux Foundation's OS-Climate is a breakthrough initiative creating a transparently governed public utility of open data and open source tools for climate-aligned finance investing, business, and regulation.
  • The Linux Foundation is the world's leading home for collaboration on open source software, hardware, standards, and data.

Global Impact, on Behalf of the Alliance for Advancing Health Online (AAHO), Shares Research and Announces Upcoming New Program at 75th World Health Assembly

Retrieved on: 
Wednesday, May 25, 2022

The global research is intended to reveal insights on how to harness social media and online engagement to drive vaccine confidence.

Key Points: 
  • The global research is intended to reveal insights on how to harness social media and online engagement to drive vaccine confidence.
  • Global Impact sought proposals that address how social media can be best utilized to better understand vaccine hesitancy and increase vaccination confidence and uptake.
  • Through these partnerships, Global Impact has raised nearly $2 billion for causes such as disaster relief and global development.
  • Global Impacts reach and services are complemented by the work of its subsidiary company, Geneva Global .

The Galien Foundation Announces Winners of the 2022 Prix Galien UK Awards at the Natural History Museum, London

Retrieved on: 
Friday, May 13, 2022

LONDON, May 13, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, announced winners for the 2022 Prix Galien UK Awards last night at the Natural History Museum, London. Awards for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" were awarded to industry leaders dedicated to innovation that improves the human condition. In conjunction with the Prix Galien UK Awards, The Galien Foundation also announced winners for the 2022 Prix Galien International Awards for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Vaccine."

Key Points: 
  • Former Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA
    Professor of Internal Medicine and Therapeutics & Founder, Former President
    Honorary Distinguished Professor of Medicine, Imperial College, Committee Chair, Prix Galien UK Awards Committee
    The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health.
  • The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.
  • Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.